Radioisotopes for the palliation of metastatic bone cancer: A systematic review

Lancet Oncology

Volumn 6, Issue 6, 2005, Pages 392-400

  Finlay, Ilora G ^a   Mason, Malcolm D ^a   Shelley, Mike ^a  

^a VELINDRE CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; ESTRAMUSTINE; ETIDRONIC ACID RE 186; ETIDRONIC ACID RE 188; HYDROCORTISONE; LEXIDRONAM SAMARIUM SM 153; MITOMYCIN; MITOXANTRONE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PACLITAXEL; PHOSPHORUS 32; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; RHENIUM 188; SAMARIUM 153; STRONTIUM 89; UNCLASSIFIED DRUG; VINBLASTINE;

ANALGESIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; BONE CANCER; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BONE SCINTISCANNING; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; CONSTIPATION; DISEASE EXACERBATION; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG PREFERENCE; DRUG USE; EUROPE; FEBRILE NEUTROPENIA; HUMAN; IMAGE ANALYSIS; LEUKOPENIA; METASTASIS; NAUSEA; NEUTROPENIA; PAIN ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; REVIEW; SEDATION; SOMNOLENCE; THROMBOCYTOPENIA; UNITED STATES;

BONE NEOPLASMS; HUMANS; NEOPLASM METASTASIS; PAIN, INTRACTABLE; PALLIATIVE CARE; RADIOISOTOPES; RADIOTHERAPY DOSAGE; RHENIUM; SAMARIUM; STRONTIUM RADIOISOTOPES;

EID: 19944386284     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(05)70206-0     Document Type: Review

References (74)

1. SH Landis T Murray S Bolden PA Wingo Cancer statistics, 1998 CA Cancer J Clin 48 1998 6-29
2. RE Coleman Metastatic bone disease: Clinical features, pathophysiology and treatment strategies Cancer Treat Rev 27 2001 165-176
3. A Lipton L Costa SM Ali LM Demers Bone markers in the management of metastatic bone disease Cancer Treat Rev 27 2001 181-185
4. C Urch The pathophysiology of cancer-induced bone pain: Current understanding Palliat Med 18 2004 267-274
5. RG Robinson GM Blake DF Preston et al. Strontium-89: Treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone Radiographics 9 1989 271-281
6. GM Blake MA Zivanovic AJ McEwan DM Ackery Sr-89 therapy: Strontium kinetics in disseminated carcinoma of the prostate Eur J Nucl Med 12 1986 447-454
7. EB Silberstein C Williams Strontium-89 therapy for the pain of osseous metastases J Nucl Med 26 1985 345-348
8. AH Laing DM Ackery RJ Bayly et al. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy Br J Radiol 64 1991 816-822
9. WC Mertens L Stitt AT Porter Strontium 89 therapy and relief of pain in patients with prostatic carcinoma metastatic to bone: A dose response relationship? Am J Clin Oncol 16 1993 238-242
10. N Firusian Endo-osseous isotope therapy of malignant skeletal disease Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 91 1978 143-156
11. RG Robinson JA Spicer DF Preston et al. Treatment of metastatic bone pain with strontium-89 Int J Rad Appl Instrum B 14 1987 219-222
12. SD Fossa E Paus M Lochoff et al. 89Strontium in bone metastases from hormone resistant prostate cancer: Palliation effect and biochemical changes Br J Cancer 66 1992 177-182
13. Y Kimura K Hamamoto M Furudate et al. Effectiveness of the radioactive strontium (89Sr) chloride agent, SMS.2P for pain palliation in patients with metastatic bone tumor in phase III multicenter clinical trial Kaku Igaku 33 1996 1347-1358
14. K Schmeler K Bastin Strontium-89 for symptomatic metastatic prostate cancer to bone: Recommendations for hospice patients Hosp J 11 1996 1-10
15. Lee C.K. Aeppli D.M. Unger J. et al. Strontium-89 chloride (Metastron) for palliative treatment of bony metastases: The University of Minnesota experience Am. J. Clin. Oncol. 1996 19 102-107
16. F Pons R Herranz A Garcia et al. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer Med Eur J Nucl 24 1997 1210-1214
17. N Baziotis E Yakoumakis A Zissimopoulos et al. Strontium-89 chloride in the treatment of bone metastases from breast cancer Oncology 55 1998 377-381
18. J Kasalicky V Krajska The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases Eur J Nucl Med 25 1998 1362-1367
19. Fuster D. Herranz R. Alcover J. et al. Treatment of metastatic bone pain with repeated doses of strontium-89 in patients with prostate neoplasm Rev Esp Med Nucl 2000 19 270-274
20. SL Turner S Gruenewald N Spry et al. Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer Br J Cancer 84 2001 297-302
21. A Dafermou P Colamussi M Giganti et al. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer Eur J Nucl Med 28 2001 788-798
22. PM Windsor Predictors of response to strontium-89 (Metastron) in skeletal metastases from prostate cancer: Report of a single centre's 10-year experience Clin Oncol 2001 13 219-227
23. C Lou D Zhang L Yu Internal strontium-89 radiotherapy for malignant bony metastasis Zhonghua Zhong Liu Za Zhi 23 2001 507-509
24. CL Rogers BL Speiser PC Ram et al. Efficacy and toxicity of intravenous strontium-89 for symptomatic osseous metastases J Brachyther Int 14 1998 133-142
25. K Buchali HJ Correns M Schuerer et al. Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma Eur J Nucl Med 14 1988 349-351
26. VJ Lewington AJ McEwan DM Ackery et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone Eur J Cancer 27 1991 954-958
27. AT Porter AJ McEwan JE Powe et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer Int J Radiat Oncol Biol Phys 25 1993 805-813
28. S Smeland B Erikstein M Aas et al. Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: Results of a double-blind randomized study Int J Radiat Oncol Biol Phys 56 2003 1397-1404
29. Oosterhof G.O. Roberts J.T. de Reijke T.M. et al. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: A phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group Eur. Urol. 2003 44 519-526
30. AJ McEwan AT Porter P Venner G Amyotte An evaluation of the safety and efficacy of treatment with strontium-89 in patients who have previously received wide field radiotherapy Antibody Immunoconjugates Radiopharmaceuticals 3 1990 91-97
31. PM Quilty D Kirk JJ Bolger et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer Radiother Oncol 31 1994 33-40
32. Dearnaley D.P. Bayly R.J. A'Hern R.P. et al. Palliation of bone metastases in prostate cancer. Hemibody irradiation or strontium-89? Clin. Oncol. 1992 4 101-107
33. KK Fu PA Rayner KN Lam Modification of the effects of continuous low dose rate irradiation by concurrent chemotherapy infusion Int J Radiat Oncol Biol Phys 10 1973 1473-1478
34. R Sciuto A Festa S Rea et al. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: A randomized clinical trial J Nucl Med 43 2002 79-86
35. R Sciuto CL Maini A Tofani et al. Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89 Nucl Med Commun 17 1996 799-804
36. Tu S.M. Millikan R.E. Mengistu B. et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomised phase II trial Lancet 2001 357 336-341
37. GJ Dickie D Macfarlane Strontium and samarium therapy for bone metastases from prostate carcinoma Australas Radiol 43 1999 476-479
38. N Nair Relative efficacy of 32P and 89Sr in palliation in skeletal metastases J Nucl Med 40 1999 256-261
39. R Sciuto A Festa R Pasqualoni et al. Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients Breast Cancer Res Treat 66 2001 101-109
40. Liepe K. Franke W.G. Kropp J. et al. Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases Nuklearmedizin 2000 39 146-151
41. I Resche JF Chatal A Pecking et al. A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases Eur J Cancer 33 1997 1583-1591
42. JF Eary C Collins M Stabin et al. Samarium-153-EDTMP biodistribution and dosimetry estimation J Nucl Med 34 1993 1031-1036
43. JH Turner PG Claringbold EL Hetherington et al. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases J Clin Oncol 7 1999 1926-1931
44. M Farhanghi RA Holmes WA Volkert et al. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer J Nucl Med 33 1992 1451-1458
45. C Collins JF Eary G Donaldson et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: A phase I/II trial J Nucl Med 34 1993 1839-1844
46. PM Anderson GA Wiseman et al. A Dispenzieri High-dose samarium-153 ethylene diamine tetramethylene phosphonate: Low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases J Clin Oncol 20 2002 189-196
47. O Enrique P Zhongyun E Patrma et al. Efficacy and toxicity of Sm-153 EDTMP in the palliative treatment of painful bone metastases World J Nucl Med 1 2002 21-27
48. AS Alberts BJ Smit WK Louw et al. Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone Radiother. Oncol. 1997 43 175-179
49. L Li Z Liang H Deng et al. Samarium-153-EDTMP bone uptake rate and its relation to therapeutic effect Chin Med J 115 2002 1096-1098
50. J Tian L Cao J Zhang et al. Comparative analysis of patients not responding to a single dose of 153Sm-EDTMP palliative treatment for painful skeletal metastases Chin Med J 115 2002 824-828
51. CY Jiang BL Zhu YJ Zhang The value of Sm-153-EDTMP for treatment of metastatic bone pain and improving quality of life Zhonghua Zhong Liu Za Zhi 16 1994 118-121
52. H Wu T Tan L Fang X Zhang Evaluation of efficacy of 153Sm-EDTMP in patients with painful bone metastases of breast cancer Sichuan da Xue Xue Bao Yi Xue Ban 34 2003 716-718
53. J Dolezal J Vizd'a E Cermakova et al. Effect of Samarium-153-EDTMP treatment in patients with painful bone metastases Ceska Radiologie 57 2003 184-191
54. JH Turner PG Claringbold A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate Eur J Cancer 27 1991 1084-1086
55. AN Serafini SJ Houston I Resche et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled clinical trial J Clin Oncol 16 1998 1574-1581
56. O Sartor RH Reid PJ Hoskin et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer Urology 63 2004 940-945
57. de Klerk J.M. Zonnenberg B.A. van het Schip A.D. et al. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer Eur. J. Nucl. Med. 1994 21 1114-1120
58. de Klerk J.M. van het Schip A.D. Zonnenberg B.A. et al. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer J. Nucl. Med. 1996 37 244-249
59. HR Maxon 3rd LE Schroder SR Thomas et al. Re-186(Sn) HEDP for treatment of painful osseous metastases: Initial clinical experience in 20 patients with hormone-resistant prostate cancer Radiol 176 1990 155-159
60. C Giannakenas HP Kalofonos DJ Apostolopoulos et al. Preliminary results of the use of Re-186-HEDP for palliation of pain in patients with metastatic bone disease Am J Clin Oncol 23 2000 83-88
61. H Kolesnikov-Gauthier P Carpentier P Depreux et al. Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer J Nucl Med 41 2000 1689-1694
62. R Sciuto A Tofani A Festa et al. Short- and long-term effects of 186Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases J Nucl Med 41 2000 647-654
63. NO Kucuk E Ibis G Aras et al. Palliative analgesic effect of Re 186 HEDP in various cancer patients with bone metastases Ann Nucl Med 14 2000 239-245
64. JM Quirijnen SH Han BA Zonnenberg et al. Efficacy of rhenium-186-etidronate in prostate cancer patients with metastatic bone pain J Nucl Med 37 1996 1511-1515
65. SH Han BA Zonneberg JM de Klerk et al. 186Re-etidronate in breast cancer patients with metastatic bone pain J Nucl Med 40 1999 639-642
66. HR Maxon 3rd LE Schroder VS Hertzberg et al. Rhenium-186(Sn) HEDP for treatment of painful osseous metastases: Results of a double-blind crossover comparison with placebo J Nucl Med 32 1991 1877-1881
67. SH Han JM de Klerk S Tan et al. The PLACORHEN study: A double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium J Study Nucl Med 43 2002 1150-1156
68. K Liepe R Hliscs J Kropp et al. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases J Nucl Med 44 2003 953-960
69. H Palmedo S Guhlke H Bender et al. Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases Eur J Nucl Med 27 2000 123-130
70. S Li J Liu H Zhang et al. Rhenium-188 HEDP to treat painful bone metastases Clin Nucl Med 26 2001 919-922
71. K Liepe R Hliscs J Kropp et al. Rhenium-188-HEDP in the palliative treatment of bone metastases Cancer Biother Radiopharm 15 2000 261-265
72. S Chen K Xu D Yao et al. Treatment of metastatic bone pain with Rhenium-188 hydroxyethylidene disphosphate Med Princ Pract 10 2001 98-101
73. H Palmedo A Manka-Waluch P Albers et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: Randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate J Clin Oncol 21 2003 2869-2875
74. Schraml F.V. Parr L.F. Ghurani S. Silverman E.D. Autopsy of a cadaver containing strontium-89-chloride J. Nucl. Med. 1997 38 380-382